MEDIBIOFARMA SL
To make disease-modifying treatments available to patients with serious or life-threatening conditions
To make disease-modifying treatments available to patients with serious or life-threatening conditions
MEDIBIOFARMA SL is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. The company's slogan "To make disease-modifying treatments available to patients with serious or life-threatening conditions" encapsulates its vision. Medibiofarma aims to generate innovative and high-quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Specializing in Biotechnology and Health Care, the company is headquartered in Spain. The latest investment, a grant investment at 20 March 2023, came from the Crohn's & Colitis Foundation. This shows the confidence that notable organizations have in MEDIBIOFARMA SL's potential to develop disease-modifying treatments.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | €1.00M | 2 |
|
03 Apr 2024 |
| Grant | Unknown | 1 |
|
20 Mar 2023 |
| Venture Round | €300.00K | 1 |
|
15 Mar 2022 |
| Funding Round | €115.00K | 1 |
|
01 Jan 2020 |
| Funding Round | $1.00M | 1 |
|
01 Jan 2019 |
No recent news or press coverage available for MEDIBIOFARMA SL.
-logo.jpg){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.